Anthony Fauci Director, National Institute of Allergy and Infectious Diseases, USA Kiran Mazumdar-Shaw Chairperson and Managing Director of Biocon, India Sir Andrew Witty Chief Executive Officer, GlaxoSmithKline, UK Arthur D. Levinson Chief Executive Officer, Calico, USA Heather Bresch Chief Executive Officer, Mylan Raman Singh President, Mundipharma Asia Pacific, Latin America, Middle East and Africa Peter Seeberger Director at the Max-Planck Institute for Colloids and Interfaces, and Professor, Free University of Berlin, Germany Pascal Soriot Executive Director and Chief Executive Officer, AstraZeneca Robin Robinson Director of Biomedical Advanced Research and Development Authority; Deputy Assistant Secretary for Preparedness & Response, US Department of Health and Human Services Robert A. Bradway Chairman and Chief Executive Officer, Amgen John Talley Chief Scientific Officer, Euclises Pharmaceuticals Carsten Brockmeyer Chief Executive Officer, Formycon AG Kenneth C. Frazier Chairman of the Board and Chief Executive Officer, MSD. Ruth McKernan Chief Executive, Innovate UK David Bentley Vice President and Chief Scientist, Illumina Severin Schwan Chief Executive Officer, Roche Group Carl June Richard W. Vague Professor in Immunotherapy, Department of Pathology and Laboratory Medicine, University of Pennsylvania, USA David Baltimore President Emeritus and Robert Andrews Millikan Professor of Biology, California Institute of Technology, USA Rino Rappuoli Former Global Head of Research and Development for Novartis Vaccines Robert Langer David H. Koch Institute Professor, Massachusetts Institute of Technology, USA Lamberto Andreotti Chief Executive Officer, Bristol-Myers Squibb Lisa Anson President, AstraZeneca UK and Ireland Alan Armstrong Chairman & Group Chief Executive Officer, Almac Group John Aunins Executive Vice President and Chief Technology Officer, Seres Health, USA Stéphane Bancel Chief Executive Officer, Moderna Therapeutics Richard Bergström Director General, European Federation of Pharmaceutical Industries and Associations (EFPIA) Olivier Brandicourt Chief Executive Officer, Sanofi Barry Buckland Chief Executive Officer, BiologicB, USA Pierre Chambon Professor of Molecular Genetics, Institute of Advanced Studies, Strasbourg University, France John Chiminski President and Chief Executive Officer, Catalent William Chin Executive Vice President, Scientific and Regulatory Affairs, Pharmaceutical Research and Manufacturers of America (PhRMA) Marshall Crew Global PDS Scientific Excellence, Patheon Francis S. Collins Director, US National Institutes of Health, USA Charles Cooney Robert T. Haslam (1911) Professor of Chemical Engineering Emeritus, Department of Chemical Engineering, Massachusetts Institute of Technology, USA Meindert Danhof Professor of Pharmacology and former Scientific Director of the Leiden Academic Center for Drug Research (LACDR), Leiden University, the Netherlands Marijn Dekkers Chairman of the Board of Management, Bayer AG Sir Andrew Dillon Chief Executive of the National Institute for Health and Care Excellence (NICE), UK Joseph Famulare Vice President, Global Quality Compliance and External Collaboration, Genentech John P. Farris President and Chief Executive Officer, SafeBridge Consultants, USA Dennis Fenton Retired Mark C. Fishman President, Novartis Institutes for Biomedical Research Chris Frampton Professor of Structural Chemistry and Crystal Engineering, Wolfson Centre for Materials Processing, Brunel University, UK Parrish Galliher Chief Technology Officer, Xcellerex, Life Sciences from GE Healthcare Kenneth Getz Director, Sponsored Research Programs and Associate Professor, CSDD, Tufts University School of Medicine; Founder and Board Chair, CISCRP Dalvir Gill Chief Executive Officer and Member of the Board of Directors, TransCelerate BioPharma Jane Griffiths Company Group Chairman, Janssen EMEA Yoshihiko Hatanaka Chief Executive Officer and President, Astellas Pharma Richard Heyman Founder, Aragon and Seragon Robert J. Hugin Chairman and Chief Executive Officer, Celgene Ajaz Hussain Executive Director, The National Institute for Pharmaceutical Technology and Education, USA Tyler Jacks David H. Koch Professor; Director, Koch Institute for Integrative Cancer Research; Investigator, Howard Hughes Medical Institute, USA Dennis R. Jenke Baxter Distinguished Scientist, Baxter Healthcare Corporation Joseph Jimenez Chief Executive Officer, Novartis William G. Kaelin Professor of Medicine, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School; Investigator, Howard Hughes Medical Institute; and Associate Director, Basic Science, Dana-Farber Cancer Institute/Harvard Cancer Center Jeff Kasher President, Patients Can’t Wait, LLC Joseph Kim Senior Advisor in Clinical Innovation, Eli Lilly Andreas Koester Vice President, Clinical Trial Innovation, Janssen R&D, Janssen Pharmaceutical Companies of Johnson & Johnson Daniel S. Kohane Professor of Anaesthesia, Harvard Medical School, USA John C. Lechleiter Chairman, President and Chief Executive Officer, Eli Lilly and Company Wim Leereveld Founder and CEO, Access to Medicine Foundation Craig Lipset Head of Clinical Innovation, Worldwide Research & Development, Pfizer Archie Lovatt Scientific Operations Director, SGS Life Sciences Anthony S. Lubiniecki Senior Scientific Director & Fellow, Chemistry, Manufacturing & Controls (CMC) Strategy, Pharmaceutical Development & Manufacturing Sciences, Janssen R&D Claus-Michael Lehr Professor, Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS); Helmholtz Center for Infection Research (HZI); Saarland University, Germany Louis Monti Executive Vice-President and Secretary, Pherin Pharmaceuticals Julian Morris Emeritus Professor of Process Control, Newcastle University, UK and Technical Director, Centre for Process Analytics and Control Technology (CPACT) Randy Mrsny Professor, Department of Pharmacy and Pharmacology, University of Bath, UK Tarit Mukhopadhyay Lecturer, Vaccine Bioprocess Development, University College London, UK Kary Mullis Chief Scientific Advisor for Altermune Technologies George Nakayama Representative Director; President and Chief Executive Officer, Daiichi Sankyo Co., Japan Mark Offerhaus Founder and CEO, Micreos, The Netherlands Julie O’Neill Executive Vice President, Global Operations, Alexion, Ireland Stephen Ostroff Acting Commissioner of Food and Drugs, FDA Brian Overstreet Co-Founder and President, AdverseEvents Ulo Palm Senior Vice President Branded Drug Development Operations, Actavis Pharmaceuticals Alain Pralong VP New Product Introduction & Technical Life Cycle Management, GSK David E.I. Pyott Former Chairman and CEO, Allergan Ian C. Read Chairman of the Board and Chief Executive Officer, Pfizer Joerg Reinhardt Chairman of the Board of Directors, Novartis AG Tomasz Sablinski Co-founder & CEO, Transparency Life Sciences Charles L. Sawyers Memorial Sloan-Kettering Cancer Center; investigator at Howard Hughes Medical Center, USA George A. Scangos Chief Executive Officer, Biogen Idec Joseph Schlessinger William H. Prusoff Professor of Pharmacology and Chair of the Pharmacology section, Yale School of Medicine; Director, Yale Cancer Biology Institute Andreas Seidel-Morgenstern Director, Department of Physical and Chemical Foundation of Process Engineering, Max Planck Institute for Dynamics of Complex Technical Systems, Germany Andy Skibo Head of Global Biologics Operations and Global Engineering at AstraZeneca/MedImmune Manish Soman President and CEO, Sciformix Lars Rebien Sørensen Chief Executive Officer, Novo Nordisk A/S Indresh K. Srivastava Vice President, Product Realization, Protein Sciences Abbe Steel Founder and CEO, HealthiVibe Marco Taglietti CEO, Scynexis, USA Nigel Theobald Founder and CEO, N4 Pharma, UK Bernhardt Trout Raymond F. Baddour, ScD, (1949) Professor of Chemical Engineering, MIT and Director, Novartis-MIT Center for Continuous Manufacturing, USA Catherine Tuleu Director, Centre for Pediatric Pharmacy Research, UCL School of Pharmacy, UK Harold Varmus Lewis Thomas University Professor at Weill Cornell Medical College, USA J. Craig Venter Founder, Chairman, and CEO of the J. Craig Venter Institute (JCVI), USA Jens H. Vogel Global Head, CMC Strategy & TRA, Boehringer Ingelheim Biopharmaceuticals, Germany J. Michael Wallace Director, Global Standards & Serialization, Abbott Laboratories, USA Keith Williams Founder and Managing Director, GXPi and Formpipe Vikramaditya G. Yadav Assistant Professor, Department of Chemical and Biological Engineering, The University of British Columbia, Canada Shinya Yamanaka Director and Professor, Center for iPS Cell Research and Application (CiRA), Kyoto University, Japan
